发布求助
文献互助 智能选刊 最新文献

Neurodegenerative disease management最新文献

筛选
英文 中文
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary. 在为期2年的clarity - ms研究中，使用克拉德滨片治疗复发性多发性硬化症患者的生活质量改善：简单的语言总结。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-12-16 DOI: 10.1080/17582024.2024.2429970
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maidal, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Xavier Montalban, Eva Kubala Havrdova
{"title":"Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary.","authors":"Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maidal, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Xavier Montalban, Eva Kubala Havrdova","doi":"10.1080/17582024.2024.2429970","DOIUrl":"10.1080/17582024.2024.2429970","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"193-201"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care. 绘制伴有轴突球和色素小体的成人型白质脑病患者和护理伙伴的心路历程图：制定改善护理的框架。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-10-03 DOI: 10.1080/17582024.2024.2404378
Holly A Rutherford, Beth K Rush, Adam Smith, Erin Sullivan, Clarissa Martinez-Rubio, Ali Toumadj, Roberta La Piana, Cynthia Cassandro
{"title":"Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care.","authors":"Holly A Rutherford, Beth K Rush, Adam Smith, Erin Sullivan, Clarissa Martinez-Rubio, Ali Toumadj, Roberta La Piana, Cynthia Cassandro","doi":"10.1080/17582024.2024.2404378","DOIUrl":"10.1080/17582024.2024.2404378","url":null,"abstract":"<p><p><b>Aim:</b> To identify and raise awareness of healthcare service gaps for individuals with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).<b>Materials & methods:</b> An ALSP patient journey map from symptom onset throughout disease course was developed using existing literature, patient and clinician feedback from a structured workshop and community survey data regarding attitudes toward genetic testing.<b>Results:</b> ALSP diagnosis is frequently delayed due to low awareness of this rare condition and symptom overlap with more common neurological conditions. Multiple factors impact patients' decision-making regarding genetic testing for ALSP, symptom management and participation in research studies.<b>Conclusion:</b> These results highlight the challenges faced by individuals with ALSP and should support program development to improve patient care.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"161-172"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator. 利用 Percept™ 可充电神经刺激器对帕金森病进行局部场电位引导编程的当前和未来应用。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1080/17582024.2024.2404386
Weerawat Saengphatrachai, Joohi Jimenez-Shahed
{"title":"Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator.","authors":"Weerawat Saengphatrachai, Joohi Jimenez-Shahed","doi":"10.1080/17582024.2024.2404386","DOIUrl":"10.1080/17582024.2024.2404386","url":null,"abstract":"<p><p>Deep brain stimulation (DBS) has been established as an effective neuromodulatory treatment for Parkinson's disease (PD) with motor complications or refractory tremor. Various DBS devices with unique technology platforms are commercially available and deliver continuous, open-loop stimulation. The Percept™ family of neurostimulators use BrainSense™ technology with five key features to sense local field potentials while stimulating, enabling integration of physiologic data into the routine practice of DBS programming. The newly approved Percept™ rechargeable RC implantable pulse generator offers a smaller, thinner design and reduced recharge time with prolonged recharge interval. In this review, we describe the application of local field potential sensing-based programming in PD and highlight the potential future clinical implementation of closed-loop stimulation using the Percept™ RC implantable pulse generator.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"131-147"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Walking performance differs between people with multiple sclerosis who perform distinct types of exercise. 多发性硬化症患者在进行不同类型的运动时，步行表现也不尽相同。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/17582024.2024.2389037
Kristin A Johnson, Victoria M Bandera, Manfred Diehl, Heather J Leach, Brett W Fling
{"title":"Walking performance differs between people with multiple sclerosis who perform distinct types of exercise.","authors":"Kristin A Johnson, Victoria M Bandera, Manfred Diehl, Heather J Leach, Brett W Fling","doi":"10.1080/17582024.2024.2389037","DOIUrl":"10.1080/17582024.2024.2389037","url":null,"abstract":"<p><p><b>Aim:</b> To determine whether walking performance differed between people with multiple sclerosis (MS) who performed distinct types, volumes and intensities of exercise.<b>Materials & methods:</b> Forty-five people with relapsing-remitting MS performed two trials of the 2-min walk test, one at a preferred speed and another at a fast speed. Gait metrics were measured by wireless inertial sensors. Participants reported the type (aerobic, resistance), volume and intensity of exercise performed.<b>Results:</b> Walking speed reserve and gait variability were better in participants who performed combined aerobic and resistance exercises compared with those who performed aerobic-only exercise.<b>Conclusion:</b> Walking performance differs in people with mild MS disability based on the type and volume of exercise performed.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"75-85"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tofersen for SOD1 ALS. Tofersen 用于 SOD1 ALS。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-09-27 DOI: 10.1080/17582024.2024.2402216
William H Everett, Robert C Bucelli
{"title":"Tofersen for SOD1 ALS.","authors":"William H Everett, Robert C Bucelli","doi":"10.1080/17582024.2024.2402216","DOIUrl":"10.1080/17582024.2024.2402216","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative condition affecting the motor system. The heterogenous nature of ALS complicates trial design. Genetic forms of ALS present an opportunity to intervene in a less heterogeneous population. ALS associated with gain of function mutations in <i>SOD1</i> make 'knock-down' strategies an attractive therapeutic approach. Tofersen, an antisense oligonucleotide that reduces expression of SOD1 via RNAase mediated degradation of <i>SOD1</i> mRNA, has shown robust effects on ALS biomarkers. While a Phase III trial of tofersen failed to meet its primary end point, open label extension data suggests that tofersen slows progression of SOD1 ALS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"149-160"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis. 骨髓间充质干细胞衍生的细胞外囊泡输注治疗肌萎缩性脊髓侧索硬化症。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-05-28 DOI: 10.1080/17582024.2024.2344396
Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner
{"title":"Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis.","authors":"Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner","doi":"10.1080/17582024.2024.2344396","DOIUrl":"10.1080/17582024.2024.2344396","url":null,"abstract":"<p><p><b>Background:</b> In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.<b>Methods:</b> Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.<b>Results:</b> There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.<b>Conclusion:</b> HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"14 3-4","pages":"111-117"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies. 神经丝蛋白轻链：处于基因导向疗法清晰与混乱交叉点的生物标志物。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-11-15 DOI: 10.1080/17582024.2024.2421738
Michael Christian A Virata, Jesus Alfonso Catahay, Giuseppe Lippi, Brandon M Henry
{"title":"Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.","authors":"Michael Christian A Virata, Jesus Alfonso Catahay, Giuseppe Lippi, Brandon M Henry","doi":"10.1080/17582024.2024.2421738","DOIUrl":"10.1080/17582024.2024.2421738","url":null,"abstract":"<p><p>Neurofilament light chain (NfL) is a promising biomarker for neurodegenerative diseases, measurable in both CSF and blood upon neuroaxonal damage. While CSF analysis was traditionally used, blood-based assays now offer a less invasive alternative. NfL levels correlate with disease severity and progression in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis and Huntington's disease. Clinical trials demonstrate its utility as a pharmacodynamic biomarker in MS and ALS. The FDA's approval of Tofersen for SOD1-ALS based on NfL reduction underscores its growing acceptance as surrogate marker. However, challenges remain in standardizing assays, interpreting clinical correlations, low specificity and understanding the dynamics between CSF and blood NfL levels. Addressing these issues is crucial for maximizing NfL's potential in neurodegenerative disease management.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"227-239"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study. 酮饮食对帕金森病症状、生物标志物、抑郁、焦虑和生活质量的影响：一项纵向研究。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-06-13 DOI: 10.1080/17582024.2024.2352394
Melanie M Tidman, Dawn Reid White, Tim A White
{"title":"Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study.","authors":"Melanie M Tidman, Dawn Reid White, Tim A White","doi":"10.1080/17582024.2024.2352394","DOIUrl":"10.1080/17582024.2024.2352394","url":null,"abstract":"<p><p><b>Aim:</b> Evidence suggests low-carbohydrate diets (LCHF) may assist in treating neurodegenerative diseases such as Parkinson's disease (PD); however, gaps exist in the literature.<b>Patients & methods:</b> We conducted a small 24-week pilot study to investigate the effects of an LCHF diet on motor and nonmotor symptoms, health biomarkers, anxiety, and depression in seven people with PD. We also captured patient experiences during the process (quality of life [QoL]).<b>Results:</b> Participants reported improved biomarkers, enhanced cognition, mood, motor and nonmotor symptoms, and reduced pain and anxiety. Participants felt improvements enhanced their QoL.<b>Conclusion:</b> We conclude that an LCHF intervention is safe, feasible, and potentially effective in mitigating the symptoms of this disorder. However, more extensive randomized controlled studies are needed to create generalizable recommendations.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"97-110"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of neuro-feedback on Alzheimer's rehabilitation: a bibliometric analysis. 神经反馈对阿尔茨海默病康复的有效性：文献计量学分析。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-12-04 DOI: 10.1080/17582024.2024.2435250
Shruti Verma, Aditya Kurdekar
{"title":"Effectiveness of neuro-feedback on Alzheimer's rehabilitation: a bibliometric analysis.","authors":"Shruti Verma, Aditya Kurdekar","doi":"10.1080/17582024.2024.2435250","DOIUrl":"10.1080/17582024.2024.2435250","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's Disease (AD) is a neurodegenerative disorder with limited treatment options. Neurofeedback, a technique that trains brainwaves, has shown promise in addressing cognitive impairments.</p><p><strong>Objectives: </strong>To conduct a bibliometric analysis to explore the current research on neurofeedback as a treatment for AD.</p><p><strong>Methods: </strong>A systematic literature review was performed based on PRISMA guidelines on 142 papers. Different bibliometric parameters like the author's country, author names, keywords, journal names, and country of citations were analyzed, and a network visualization chart was generated to understand the correlation of Alzheimer-related search terms to neurofeedback.</p><p><strong>Results: </strong>Research is concentrated in Europe and North America, with a significant gap in Asian countries. A growing body of evidence supports the potential benefits of neurofeedback for AD. A strong correlation has been found between neurofeedback and AD-related terms. Clinical trials suggest positive outcomes for neurofeedback in improving cognitive impairments and working memory.</p><p><strong>Conclusion: </strong>Neurofeedback shows promise as a potential treatment for AD. Further research and clinical studies are needed to explore the full potential of neurofeedback for enhancing the quality of life for individuals with AD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"257-266"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab. 纳他珠单抗与奥克雷珠单抗治疗神经系统疾病患者生活质量有临床意义改善的时间比较。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-04-16 DOI: 10.2217/nmt-2023-0047
Carrie M Hersh, Menglan Pang, Deborah M Miller, Marisa P McGinley, Megan Hyland, Tjalf Ziemssen, Robin L Avila
{"title":"Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab.","authors":"Carrie M Hersh, Menglan Pang, Deborah M Miller, Marisa P McGinley, Megan Hyland, Tjalf Ziemssen, Robin L Avila","doi":"10.2217/nmt-2023-0047","DOIUrl":"10.2217/nmt-2023-0047","url":null,"abstract":"<p><p><b>Aim:</b> To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. <b>Methods:</b> Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. <b>Results:</b> Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24-0.57]; p < 0.001), sleep disturbance (0.45 [0.28-0.72]; p = 0.001), social role participation (0.37 [0.21-0.66]; p = 0.001) and social role satisfaction (0.5 [0.31-0.8]; p = 0.004). <b>Conclusion:</b> Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"21-33"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信